FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the appointment of Joanne Quan, MD as Chief Medical Officer. Dr. Quan will lead the global clinical development, clinical operations, and safety programs for Mirum’s pipeline of programs addressing rare diseases.
Dr. Quan was most recently Chief Medical Officer at Nuvig Therapeutics. Prior to Nuvig, she served in the same role at Modis Therapeutics, a company focused on rare genetic diseases (acquired by Zogenix, Inc. and subsequently UCB). Before Modis, she held clinical development leadership positions at Eiger Biopharmaceuticals, InterMune, Arena Pharmaceuticals, Bayhill Therapeutics, ALZA Corporation (Johnson and Johnson), Genentech, and PathoGenesis. Dr. Quan received a BA in molecular biology at the University of California, Berkeley, and an MD at Stanford University School of Medicine. She completed a residency in internal medicine at Massachusetts General Hospital and a fellowship in pulmonary and critical care medicine at the University of Washington.
In tandem with Dr. Quan’s appointment, Mirum announced the promotion of Peter Radovich to President and Chief Operating Officer. Mr. Radovich oversees commercial, corporate development and supply chain functions for Mirum.
“Joanne brings nearly three decades of experience in the development of medications for rare conditions. I’m thrilled that she is joining at such an exciting time for Mirum, strengthening our team and leadership in rare disease,” said Chris Peetz, Chief Executive Officer at Mirum. “I am also excited about the promotion of Peter Radovich, whose contributions have helped place Mirum in a position of strength, with an expanded portfolio of three growing commercial medicines. I am proud of the expertise we have assembled at Mirum to bring life-changing medicines to patients around the world.”
“Mirum has achieved wonderful success both clinically and commercially, establishing itself as the leader in cholestatic liver disease with a deep and focused commitment to patients,” said Joanne Quan, MD. “I am excited to join at such an important time as the company grows its pipeline, continues to extend its reach to patients globally, and builds upon its success and commitment as a rare disease company.”
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, Cholbam® (cholic acid) capsules, and Chenodal® (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in Canada. Mirum has also submitted LIVMARLI for approval in the U.S. in cholestatic pruritus in PFIC patients three months of age and older and in Europe in PFIC for patients two months of age and older. Cholbam is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme defects and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. Chenodal has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).
Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, Chenodal, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX.
To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter.
